Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2 (IC-COVID-19)
Expert Statements on Infection Control in Intensive Care Unit for Severe Acute Respiratory Syndrome Coronavirus 2
Panoramica dello studio
Stato
Descrizione dettagliata
The COVID-19 pandemic has resulted in a considerable change in the infection control protocols in the hospitals, especially ICU. The ICU management of these patients requires robust infection control measures in order to prevent cross-transmission of SARS-CoV-2 (to healthcare workers (HCWs) and other patients) and hospital acquired bacterial or fungal infections. The understanding of epidemiological characteristics of SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19) along with evidence on transmission of SARS-COV-2 in controlled healthcare-setting is still evolving. The mode of transmission of SARS-CoV-2 is airborne, through droplets or fomites. Respiratory interventions performed in these patients in ICU, such as non-invasive ventilation, high flow nasal oxygen or tracheal intubation are considered to be aerosol generating procedures and may lead to airborne transmission of SARS-CoV-2. In the absence of the robust evidence, there are no specific recommendations available on infection control of SARS-CoV-2 in ICU.
The objective of this study is to achieve consensus statements on the infection control management of SARS-CoV-2 in ICU.
The whole process of this study will be done in the form of three-four rounds of Google Forms-based Delphi surveys. The survey questionnaire, will be prepared by the investigators after systematic search of available literature and concern areas in the infection control of SARS-CoV-2 in ICU. The objective is to achieve consensus statements on the infection control management of SARS-CoV-2 in ICU.
The survey questionnaire is divided into five sections: 1.Design and engineering 2.Health-care workers and visitors 3. Personal protective equipment 4. Patient and procedures 5. Disinfection and sterilisation.
The majority of these questionnaire statements are to be rated on Likert scale and others have multiple choices. The participating experts comments and feedback will be collected through comment section after each question in round one. All the subsequent surveys will be iterative and the experts can give their opinion in each round using either open text or directly to steering group of investigators.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Dubai, Emirati Arabi Uniti, 7832
- NMC Specialty Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion criteria for participants Health care professionals involved in the management of COVID-19 patients with publications and expertise in infectious disease, infection control, sepsis, respiratory failure or public health.
Exclusion Criteria:
- Those who do not accept the invitation or not meeting any of the inclusion criteria.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Consensus using participating experts opinions.
Lasso di tempo: 30 days
|
For statements with responses on an ordinal 7-point Likert scale, 'agreement' is defined as a score of 5-7, 'neutral' by a score of 4 and 'disagreement' by a score of 1-3. Consensus is defined as achieved when >70% of the experts voted for a given option in Likert scale statement. Median and interquartile range (IQR) were used to describe the central tendency and dispersion of responses. For multiple-choice questions (MCQs), consensus is defined as achieved if >80% of the experts voted for a particular option. Stability in the responses will be assessed from round two onwards. Stability will be assessed between the two concluding rounds for each statement, using the non-parametric chi square (χ2) test. p < 0·05 is considered as a significant variation or unstable. |
30 days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Sheila Myatra, MD, Tata Memorial Hospital, Mumbai, India
Pubblicazioni e link utili
Pubblicazioni generali
- Odor PM, Neun M, Bampoe S, Clark S, Heaton D, Hoogenboom EM, Patel A, Brown M, Kamming D. Anaesthesia and COVID-19: infection control. Br J Anaesth. 2020 Jul;125(1):16-24. doi: 10.1016/j.bja.2020.03.025. Epub 2020 Apr 8.
- Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anaesth. 2020 May;67(5):568-576. doi: 10.1007/s12630-020-01591-x. Epub 2020 Feb 12.
Collegamenti utili
- Center for Disease Control and Prevention (CDC). Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. Updated November 4, 2020.
- World Health Organisation (WHO). Infection prevention and control guidance - (COVID-19). Updated September 11, 2020.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Infezioni da Coronaviridae
- Infezioni da Nidovirus
- Infezioni da virus a RNA
- Malattie virali
- Infezioni delle vie respiratorie
- Malattie delle vie respiratorie
- Polmonite, virale
- Polmonite
- Malattie polmonari
- Attributi della malattia
- Grave sindrome respiratoria acuta
- COVID-19
- Infezioni da coronavirus
- Infezioni
- Malattie trasmissibili
Altri numeri di identificazione dello studio
- NMCSpecialtyH
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezione da coronavirus
-
Salvacion USA Inc.Completato
-
Texas A&M UniversityM.D. Anderson Cancer Center; Baylor College of Medicine; Cedars-Sinai Medical Center e altri collaboratoriCompletatoInfezione da coronavirus | Coronavirus | Coronavirus come causa di malattie classificate altroveStati Uniti
-
Beijing Ditan HospitalSconosciuto
-
Janssen Vaccines & Prevention B.V.Completato
-
OSF Healthcare SystemTerminatoCOVID-19 | Infezione da coronavirus | COVID | Infezione da coronavirus | Coronavirus | SARS-CoV-2 | Coronavirus associato alla SARS come causa di malattia classificata altrove | Malattia di coronavirus | Coronavirus Sars-Associato come causa di malattia classificata altrove | Coronavirus come causa di malattie...Stati Uniti
-
Maimonides Medical CenterTerminato
-
Qilu Hospital of Shandong UniversityReclutamentoCoronavirus | Medicina tradizionale cineseCina
-
Level 42 AI, Inc.Johns Hopkins University; Schmidt FuturesCompletatoInfezione da coronavirus | CoronavirusStati Uniti
-
NPO PetrovaxCompletatoInfezioni, CoronavirusBielorussia, Federazione Russa
-
Bursa Yüksek İhtisas Education and Research HospitalSconosciutoCoronavirus come causa di malattie classificate altroveTacchino